Understanding the microRNA signature associated with Reye's syndrome

Reye's syndrome, an uncommon and potentially deadly childhood disease, is characterized by sudden noninflammatory brain dysfunction combined with hepatic dysfunction caused by the accumulation of fat. It was initially identified by Australian pathologist R.D.K. Reye in 1963. National monitoring of Reye's syndrome commenced in the United States in the early 1970s, resulting in strict cautions about the use of aspirin in children. MicroRNA (miRNA), small (~ 22 nt) non-coding RNA that regulate gene expression by reducing mRNA levels, plays a critical role in the onset and advancement of Reye's syndrome. It can affect numerous target proteins, significantly contributing to the substantial abnormalities in the syndrome's cause and development. The review thoroughly explores the influence of miRNAs on liver enzyme metabolism, emphasizing their involvement in the disruption of these enzymes and in cerebral edema as well as hepatomegaly where they contribute to the occurrence of Reye's syndrome. A comprehensive understanding of the role of miRNAs in hepatic metabolism and cerebral edema is essential for developing effective treatments aimed at diseases resulting from disrupted mitochondrial and enzymatic metabolism.